Dublin, Ireland - May 9, 2016, Dublin, Ireland - Endo International plc, a pharmaceutical company, announced the appointment of Douglas S. Ingram and Todd B. Sisitsky to its board of directors.
Article continues below
Mr. Ingram brings 20 years of biotech, pharmaceutical and medical device leadership and operational experience to Endo. He currently serves as Chief Executive Officer of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders.
Until March 2015, Mr. Ingram was the president of Allergan, Inc., a global pharmaceutical company.
Prior to serving as Allergan's president, Mr. Ingram led Allergan's operations in Europe, Africa and the Middle East.
Previously, he was Allergan's executive vice president, chief administrative officer and secretary, leading Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety and Global Corporate Affairs and Public Relations.
Prior to joining Allergan in 1996, he was an attorney at Gibson, Dunn & Crutcher LLP.
Mr. Ingram received his Juris Doctor, summa cum laude, from the University of Arizona and his bachelor of science, magna cum laude, from Arizona State University.
Mr. Sisitsky is the Managing Partner of TPG Capital, a member of the TPG Executive Committee, and co-leads the firm's investment activities in the healthcare services and pharmaceutical/medical device sectors.
He has held leadership roles in TPG's investments in Aptalis, Biomet, Fenwal, Healthscope, IASIS Healthcare, Immocur, IMS Health, Surgical CareAffiliates and Par Pharmaceutical.
Prior to joining TPG in 2003, Mr. Sisitsky worked at Forstmann Little & Company and Oak Hill Capital Partners.
He received an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude.
Mr. Sisitsky also serves on the Campaign for Tobacco-Free Kids Board of Directors as well as the Dartmouth Medical School Board of Overseers.
Endo also announced that Brian Lortie, President, U.S. Branded Pharmaceuticals, has decided to step down from his position upon the appointment of a successor. ■